@article{40f27978eed74264b5f2c6579b9601cd,
title = "Continuation of therapeutic dose heparin for critically ill patients with COVID-19",
author = "\{REMAP-C. A. P. Investigators\} and Bradbury, \{Charlotte A.\} and Lawler, \{Patrick R.\} and McVerry, \{Bryan J.\} and Ryan Zarychanski and Farah Al-Beidh and Angus, \{Derek C.\} and Arabi, \{Yaseen M.\} and Diptesh Aryal and Djillali Annane and Abi Beane and Berry, \{Lindsay R.\} and Scott Berry and Zahra Bhimani and Shailesh Bihari and Bonten, \{Marc J.M.\} and Bradbury, \{Charlotte A.\} and Brunkhorst, \{Frank M.\} and Meredith Buxton and Adrian Buzgau and Marc Carrier and Cheng, \{Allen C.\} and Matthew Cove and Derde, \{Lennie P.G.\} and Detry, \{Michelle A.\} and Estcourt, \{Lise J.\} and Fergusson, \{Dean A.\} and Mark Fitzgerald and Fowler, \{Robert A.\} and Girard, \{Timothy D.\} and Goligher, \{Ewan C.\} and Herman Goossens and Gordon, \{Anthony C.\} and Cameron Green and Rashan Haniffa and Higgins, \{Alisa M.\} and Thomas Hills and Huang, \{David T.\} and Horvat, \{Christopher M.\} and Hunt, \{Beverley J.\} and Nao Ichihara and Devachandran Jayakumar and Anand Kumar and Laffan, \{Michael A.\} and Francois Lamontagne and Lawler, \{Patrick R.\} and Leavis, \{Helen L.\} and Lewis, \{Roger J.\} and Linstrum, \{Kelsey M.\} and Edward Litton and Elizabeth Lorenzi and Lother, \{Sylvain A.\} and Marshall, \{John C.\} and McArthur, \{Colin J.\} and McAuley, \{Daniel F.\} and Anna McGlothlin and McGuinness, \{Shay P.\} and Saskia Middeldorp and Srinivas Murthy and Zoe McQuilten and McVerry, \{Bryan J.\} and Mouncey, \{Paul R.\} and Neal, \{Matthew D.\} and Nichol, \{Alistair D.\} and Parke, \{Rachael L.\} and Parker, \{Jane C.\} and Asad Patanwala and Luis Reyes and Rowan, \{Kathryn M.\} and Hiroki Saito and Santos, \{Marlene S.\} and Saunders, \{Christina T.\} and Schutgens, \{Roger E.G.\} and Ary Serpa-Neto and Seymour, \{Christopher W.\} and Manu Shankar-Hari and Vanessa Singh and Stanworth, \{Simon J.\} and Timo Tolppa and Turgeon, \{Alexis F.\} and Turner, \{Anne M.\} and \{van Bentum-Puijk\}, Wilma and \{van de Veerdonk\}, \{Frank L.\} and Webb, \{Steve A.\}",
note = "Funding Information: PRL and RZ report no conflict of interest. BM reports grant funding from NIH/NHLBI, Translational Breast Cancer Research Foundation, UPMC Learning While Doing Program and Bayer; personal fees for consulting from Boehringer Ingelheim, Synairgen Research, Ltd and BioAegis, Inc. and payment for expert testimony from VeraMedica Institute, LLC. CAB reports personal fees for consulting from Bayer, BMS Pfizer, Lilly, Novartis, Amgen and honoraria for lectures from Bayer, BMS Pfizer, Janssen, Lilly, Novartis, Amgen, Sanofi. Funding Information: We are grateful to the NIHR Clinical Research Network (UK), UPMC Health System Health Services Division (US), the Canadian Institutes of Health Research (Canada) and the Direction de la Recherche Clinique et de l{\textquoteright}Innovation de l{\textquoteright}AP-HP (France) for their support of patient recruitment. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. ",
year = "2023",
month = may,
day = "31",
doi = "10.1007/s00134-023-07095-8",
language = "English",
volume = "49",
pages = "873--875",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer",
}